Comparative Pharmacology
Head-to-head clinical analysis: CAP PROFEN versus CONSENSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAP PROFEN versus CONSENSI.
CAP-PROFEN vs CONSENSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAP-PROFEN is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, reducing prostaglandin synthesis and resulting in anti-inflammatory, analgesic, and antipyretic effects.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
None Documented
None Documented
2-4 hours (terminal half-life); prolonged in elderly (up to 6 h) and renal impairment.
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Primarily renal (70-80% as unchanged drug and glucuronide conjugate), with 10-15% biliary/fecal. Less than 5% unchanged in urine.
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Category C
Category C
Opioid and NSAID Combination
Antihypertensive/NSAID Combination